Key Takeaways:
A securities class action lawsuit could have significant implications for Soleno Therapeutics, Inc. (NASDAQ: SLNO), with a looming May 5, 2026, deadline for investors to file as lead plaintiff. The suit alleges the company made materially misleading statements regarding its lead drug candidate.
The complaint, filed in the Northern District of California, alleges that during the class period of March 26, 2025, to November 4, 2025, Soleno Therapeutics failed to disclose critical safety concerns related to its drug Diazoxide Choline Controlled-Release (DCCR). Law firms, including Hagens Berman and The Law Offices of Howard G. Smith, have issued reminders to investors about the upcoming deadline.
According to the lawsuit, Soleno allegedly downplayed or concealed evidence of safety issues in its Phase 3 trial for DCCR, which is intended to treat hyperphagia in patients with Prader-Willi Syndrome (PWS). The core allegation centers on undisclosed risks of significant adverse events, particularly concerning excess fluid retention observed in clinical trial participants.
These omissions, the suit claims, painted a misleadingly positive picture of DCCR's commercial viability and safety profile. The complaint argues that the undisclosed risks could lead to lower patient adoption, prescriber reluctance, and potential regulatory action, impacting the drug's market potential. The case is named City of Pontiac Police and Fire Retirment System v. Soleno Therapeutics, Inc.
The allegations of misrepresentation pose a significant threat to Soleno's reputation and financial standing. Investors who suffered losses are urged to seek legal counsel to discuss their rights before the lead plaintiff deadline in four days.
This legal action places Soleno's primary commercial product under intense scrutiny, potentially affecting its stock performance and future financing capabilities. The outcome of the lawsuit will be closely watched, with the next major development being the court's appointment of a lead plaintiff after the May 5 deadline.
This article is for informational purposes only and does not constitute investment advice.
